Research
Hormonal
Bariatric surgery (Roux-en-Y gastric bypass) reduces the incidence of heart failure by 2-5 times compared to non-surgical patients, as observed in large Swedish registries.
Bariatric surgery significantly lowers the risk of developing heart failure (by 2-5 times) compared to non-surgical management in obese patients.
ModerateSupportsMEDIUM confidence
Large Swedish registries found that obese patients undergoing bariatric surgery had 2–5 times lower incidence of heart failure when compared with non-surgical patients (18, 19).
Why this rating
Based on registry data cited in the introduction, not primary trial data.
Source
Cardio-psycho-metabolic outcomes of bariatric surgery: design and baseline of the WAS trial
Ann-Cathrin Koschker et al. · Endocrine Connections · 2022
DOI 10.1530/ec-21-0338
rct · n=93Cited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Roux-en-Y gastric bypass (RYGB) surgery is the only treatment for morbid obesity that conveys substantial and sustained weight loss and long-term remission of obesity-related comorbidities, whereas lifestyle interventions have failed to reduce cardiovascular event rates in obese patients with type 2 diabetes.Moderate
- Intentional weight loss, particularly through bariatric surgery, is associated with improvements in New York Heart Association (NYHA) classification, diastolic function, and reductions in left ventricular (LV) mass index and left atrial size.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →